Dhaka, Bangladesh (BBN) - The board of directors of Square Pharmaceuticals has recommended 40 percent cash and 10 percent stock dividend for the 15 months period from April 01, 2015 to June 30, 2016, said an official disclosure on Monday.
The board has also approved BDT 2.50 billion for Balancing, Modernization, Rehabilitation and Expansion (BMRE), capital machineries and lands for future expansion.
The final approval will come during the annual general meeting (AGM) scheduled to be held on December 13 at 10am at Raowa Convention Hall, Mohakhali in Dhaka.
The record date for entitlement of dividend is on November 14.
The company has also reported EPS of BDT 14.80, net assert value (NAV) per share of BDT 57.08 and net operating cash flow per share (NOCFPS) of BDT 15.88 for the 15 months period ended on June 30, 2016 which was BDT 10.46, BDT 44.95 and BDT 12.21 respectively for 15 months period from Jan 2014 to March 2015.
There will be no price limit on the trading of the shares of the Company today following its corporate declaration.
Each share of the company closed at BDT 269 on Sunday.
Square Pharma was listed on the Dhaka bourse in 1995. The pharma sector company belongs to the “A” category.
The sponsor-directors own 36.34 percent stake in the Square Pharma, while institutional investors own 11.88 percent, foreign 15.71 percent and the general public 36.07 percent.
The company’s paid-up capital is BDT 6,235.87 million and authorised capital is BDT 10,000 million while total number of securities is 623,586,546, according to DSE figures.
BBN/SSR/AD